These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16627760)

  • 21. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
    Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
    Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
    Cario G; Stanulla M; Fine BM; Teuffel O; Neuhoff NV; Schrauder A; Flohr T; Schäfer BW; Bartram CR; Welte K; Schlegelberger B; Schrappe M
    Blood; 2005 Jan; 105(2):821-6. PubMed ID: 15388585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical significance of glucocorticoid induction test in Chinese childhood acute lymphoblastic leukemia].
    Fan JJ; Chai YH; Hu SY; He HL; Zhao WL; Wang Y; Li J; Lu J; Xiao PF; Sun YN; Wang W; Cao L
    Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):523-6. PubMed ID: 24267134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.
    Stow P; Key L; Chen X; Pan Q; Neale GA; Coustan-Smith E; Mullighan CG; Zhou Y; Pui CH; Campana D
    Blood; 2010 Jun; 115(23):4657-63. PubMed ID: 20304809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D
    Blood; 2000 Oct; 96(8):2691-6. PubMed ID: 11023499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
    Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
    Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
    Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
    Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
    Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.
    Ciudad J; San Miguel JF; López-Berges MC; Vidriales B; Valverde B; Ocqueteau M; Mateos G; Caballero MD; Hernández J; Moro MJ; Mateos MV; Orfao A
    J Clin Oncol; 1998 Dec; 16(12):3774-81. PubMed ID: 9850021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia.
    Chen JS; Coustan-Smith E; Suzuki T; Neale GA; Mihara K; Pui CH; Campana D
    Blood; 2001 Apr; 97(7):2115-20. PubMed ID: 11264179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.
    Rabin KR; Gramatges MM; Borowitz MJ; Palla SL; Shi X; Margolin JF; Zweidler-McKay PA
    Pediatr Blood Cancer; 2012 Sep; 59(3):468-74. PubMed ID: 22102553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. E2F3a gene expression has prognostic significance in childhood acute lymphoblastic leukemia.
    Wang KL; Mei YY; Cui L; Zhao XX; Li WJ; Gao C; Liu SG; Jiao Y; Liu FF; Wu MY; Ding W; Li ZG
    Eur J Haematol; 2014 Oct; 93(4):281-9. PubMed ID: 24758291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
    Kang H; Chen IM; Wilson CS; Bedrick EJ; Harvey RC; Atlas SR; Devidas M; Mullighan CG; Wang X; Murphy M; Ar K; Wharton W; Borowitz MJ; Bowman WP; Bhojwani D; Carroll WL; Camitta BM; Reaman GH; Smith MA; Downing JR; Hunger SP; Willman CL
    Blood; 2010 Feb; 115(7):1394-405. PubMed ID: 19880498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.